Molecules representative of different classes of chemotactic agents, including formyl-Met-LeuPhe (FMLP), CSa, leukotriene B4, platelet-activating factor, and interleukin (IL)-8, caused a rapid reduction in the IL-1 binding capacity by human polymorphonuclear leukocytes (PMN), a cell type expressing predominantly the IL-1 type II decoy receptor (IL-1 decoy RII). N-t-BocMet-Leu-Phe, an antagonist for the FMLP receptor, inhibited the loss of IL-1 binding capacity induced by FMLP. Monocyte chemotactic protein 1, a chemokine related to IL-8 but inactive on PMN, had no effect on IL-1 binding in this cell type. FMLP was selected for further detailed analysis of chemoattractant-induced loss of IL-1 binding by PMN. The action of FMLP was rapid, reaching 50% of its maximum (80%) at 30 s, the earliest measurable time point, and plateauing between 10 and 30 min. Dose-response analysis revealed that maximal reduction of IL-1 binding was reached at FMLP concentrations that were also optimal for chemotaxis (50% effective dose = 5 x 10 -9 M). The loss of IL-1 binding capacity caused by FMLP was determined by a reduction in receptor number with no change in their affinity. The effect of FMLP on IL-1 receptor (IL-1R) was selective in that the PMN surface structures IL-SR, CD16, CD18, and major histocompatibility complex class I antigens were unaffected under these conditions. Loss of surface IL-1R was not due to an augumented rate of internalization. FMLP caused rapid release of a 45-kD IL-1-binding molecule identified as the IL-1 decoy RII. After FMLP-induced release, PMN reexpressed newly synthesized receptors, reaching basal levels by 4 h. FMLP-induced release of the IL-1 decoy RII did not impair the responsiveness of PMN to IL-1 in terms of promotion of survival and cytokine production. FMLP-induced release of the IL-1 decoy RII was unaffected by protein synthesis inhibitors, was blocked by certain protease inhibitors, and was mimicked by agents (the Ca + + ionophore A23187 and phorbol myristate acetate) that recapitulate elements in the signal transduction pathway of chemoattractant receptors. The time frame and concentration range of chemoattractant-induced rapid release of the IL-1 decoy RII are consistent with the view that IL-1 decoy RII release is an early event in the multistep process of leukocyte recruitment. Rapid chemoattractant-induced IL-1 decoy RII release in the circulation may counteract IL-1 leaking into the systemic circulation from sites of inflammation while preserving the capacity of leukocytes to respond to IL-1 in tissues. This phenomenon may contribute as well to the antiinflammatory effect of systemic administration of chemotactic agents. (1, 2). IL-1 signaling activity appears to be mediated exclusively via the IL-1RI, whereas the IL-1RII has no signaling property and acts in myelomonocytic cells as a decoy for IL-1, inhibiting its activity by preventing IL-1 from binding to the IL-1RI (3, 4) .
that IL-4 (4), IL-13 (10) , and the antiinflammatory glucocorticoid, dexamethasone (11) , were potent inducers of IL-1 decoy RII expression and release in human myelomonocytic cells. Up-regulation of IL-1 decoy RII by IL-4, IL-13, and dexamethasone was gene and protein synthesis dependent. The released soluble IL-1 decoy RII retains its ability to bind IL-l~x, IL-1B, and the IL-1R antagonist, although with different relative affinities compared to the membrane-bound receptor (11) . The ability of certain cytokines and glucocorticoids to induce expression and release of a decoy target for IL-1 may contribute to the antiinfhmmatory activities of these agents (4, 11) .
Various agents, including chemotactic signals, cause rapid shedding of TNFR (12) . These previous observations prompted us to examine the regulation of IL-1 decoy RII release from human PMN exposed to chemotactic stimuli. We found that treatment of PMN with chemoattractants results in massive (up to 90%), rapid (evident within 30 s), and protein synthesis-independent release from the PMN surface of a soluble form of IL-1 decoy RII, followed by reexpression of newly synthesized receptor. This event is mediated by a preformed proteolytic enzyme. Rapid release of the IL-1 decoy RII is an early event in the multistep process of PMN recruitment, which likely plays a role in the regulation of local versus systemic inflammatory reactions.
Materials and Methods
Cells. Human PMN were separated from the peripheral blood of human healthy donors by Percoll gradient centrifugation (13) . Briefly, whole blood was fractionated by Ficoll gradient centrifugation (Seromed-Biochem KG, Berlin, Germany), and PMN, collected from the pellet, were layered on top of 62% Percoll (Pharmacia LKB, Uppsala, Sweden) after a centrifugation at 1,500 rpm for 20 min at room temperature. PMN pellets (>~98% pure as assessed by morphology) were resuspended at 107/ml in RPMI 1640 (Seromed-Biochem KG) with 2 mM glutamine (Seromed-Biochem KG) and 20 mM Hepes (Merck, Darmstadt, Germany). All reagents contained <0.125 EU/ml of endotoxin as checked by limulus amebocyte lysate assay (Microbiological Associates, Inc., P, ockvilh, MD).
Reagents. FMLP was purchased from Sigma Chemical Co. (St. Louis, MO), dissolved in ethanol at 10 -9 M, and stored at -20~ until use. Human recombinant CSa was a kind gift from Dr. H. S. Showell (Pfizer Central Research, Groton, CT). Human recombinant ID8 was from Dainippon (Osaka, Japan). Phtelet-activating factor (PAF), 1 leukotriene B4 (LTB4), A23187, PMA, and cycloheximide (CH) were purchased from Sigma Chemical Co. Human recombinant monocyte chemotactic protein (MCP)-I was from Pepro Tech Inc. (Rocky Hill, NJ).
Human recombinant Ibl/~ was obtained through the courtesy of Dr. J. E. Sims (Immunex Corp., Seattle, WA). Protease inhibitors used in this study (PMSF, N-tosyl-lysyl-chloromethyl ketone t Abbreviations used in this paper: CH, cycloheximide; LTB4, leukotriene B4; MCP, monocyte chemotactic protein; PAF, platelet-activating factor; PKC, protein kinase C; TLCK, N-tosyl-lysyl-chloromethyl ketone; TPCK, N-tosyl-phenylalanyl-choromethyl ketone.
[TICK], N-tosyl-phenylalanyl-chloromethyl ketone [TPCK] , and EGTA) were from Sigma Chemical Co. EDTA was from Merck. o~t-antitrypsin was from Calbiochem Corp. (La Jolla, CA).
ILI-Binding Assay (4, 10, 11) . Routinely, PercoU-purified PMN (107/ml) were incubated with or without the indicated stimuli in serum-free medium RPMI 1640 at 37~ in 5~ CO2 for 30 min in polypropylene 50-ml conical tubes (2070; Falcon Labware, Becton Dickinson and Co., Oxnard, CA). Next, cells were washed with binding buffer (RPMI 1640, 0.2~ BSA, pH 7.4 [Sigma Chemical Co.]), and 4 x 106 PMN were incubated with 600 pM 12sI-IL-1B (sp act 180/~Ci//~g; New England Nuclear, Bad Homburg, Germany) in the presence or absence of a 100-fold molar excess of cold cytokine in 50/.d binding buffer at 4~ for 18 h in polystyrene 96 round-bottomed well microplates (3077; Falcon Labware) on a shaking platform. Preliminary experiments showed that binding reached the plateau (8 h) under these conditions. To separate bound from free ~2sI-IL-1/~, ceils were resuspended, transferred to Eppendorf tubes, washed in binding buffer, resuspended in 70 ~l of binding buffer, and finally layered on the top of a 200-/~1 cushion of 20070 sucrose (Merck) and 107o BSA in 400-#d polypropylene tubes (342867; Beckman Instruments, Palo Alto, CA) and centrifuged at 10,000 rpm for 30 s at room temperature. The cellular pellets were counted in a gamma counter. When IL-8 binding was studied, 12sI-IL-8 (Amersham International, Little Chalfont, UK) (sp act 2,000 Ci/mmol) was used under the same experimental conditions described above. To obtain a saturation curve, untreated or FMLP-treated PMN were incubated with decreasing amounts of ~2sI-IIrl~, in the presence or absence of a 100-fold molar excess of cold cytokine. Next, Scatchard analysis was performed by the LIGAND (4.1; National Institutes of Health, Bethesda, ME)) program to determine the affinity and numbers of receptors for IblB. To investigate the kinetics of loss of II.-1 binding, PMN were in. cubated at 107/ml in RPMI 1640 at 37~ for different periods of time (30 s-30 rain) in the presence or absence of FMLP. Subsequently, cells were washed and resuspended in binding buffer to evaluate Ibl binding as previously described. When reexpression of II,1 decoy RII was studied, PMN were pretreated in medium or with FMLP for 30 min to induce release of IL-1R from PMN. PMN were then washed and incubated in 10% FCS (Hyclone Laboratories, Inc., Logan, UT) RPMI 1640 medium (recovery period) for various periods of time and tested for IL-1B binding.
ILIR Internalization. PMN (4 x 106/50/~1) were incubated in binding buffer with I nM 12sI-Ib1B for 4 h at 4~ on a shaking platform, in the presence or absence of a 100-fold molar excess of unlabeled IL-1/~. PMN were washed twice in binding buffer to remove unbound cytokine and then resuspended in serum-free medium RPMI 1640 (4 x 106/100/~1) and incubated for various periods of time at 37~ with or without 10 -7 M FMLP, to induce receptor internalization. At each time point, 4 x 106 cells were washed, acid washed for 5 min (50 mM glycine; 0.8% NaC1, pH 3) to remove surface-bound cytokine, and washed again, and pellets were counted in a gamma counter to determine the amount of internalized cytokine.
Chemotaxis Assay. The chemotactic response of human circulating PMN to FMLP was tested as described (14, 15) . Briefly, 25 _+ 1/~1 of FMLP, diluted in 1% FCS RPMI 1640, was seeded in the lower compartment of the chemotaxis chamber, and 50 #1 of cell suspension (1.5 x 106/ml) was seeded in the upper compartment.
The two compartments were separated by a 5-/~m pore size polyvinylpyrrolidone-free polycarbonate filter (Nuclepore Corp., Pleasanton, CA). Chambers were incubated at 37~ in air with 5% CO2 for 90 min. At the end of the incubation, filters were removed, fared, and stained with Diff-Quik (Harleco, Gibbstown, NJ), and five high power oil immersion fields were counted.
Flow Cytometry. The following antibodies were used for flow cytometry: The anti-CD16 mAb KD1 was a kind gift from Dr. E. Ciccone (Istituto Tumori, Genova, Italy), and anti-MHC class I molecule mAb W6/32 and anti-CD18 mAb T81/18 were from American Type Culture Collection (Rockville, MD). After treatment with FMLP for 30 min as detailed above, an aliquot of cells was examined for IL-lfl binding, and the remaining PMN were resuspended in 0.1 ml saline (Bieffe, Bergamo, Italy) with 2% human serum (pool from different healthy donors) and mAb. After 30 min of incubation on ice, cells were washed twice and resuspended in saline containing 2% human serum and a fluoresceinated antibody against mouse IgG (Becton Dickinson Immunocytometry Systems, Mountain View, CA). After 30 min on ice, cells were washed twice and analyzed by flow cytofluorometry with a FACSTAR | plus apparatus (Becton Dickinson and Co.).
Affinity Cross-linking. Cross-linking experiments were described in detail (11) . 30 x 106 PMN were stimulated with 10-7 M FMLP in I ml of KPMI 1640 at 37~ for 30 min. Medium was recovered and concentrated 10 times by membrane filtration (Amicon, Beverly, MA; cut-off 10,000). When studied, 200 #1 was added to 1 nM 128I-Ibl/3, with or without a 200-M excess of cold II~1/3 or 10 /~g/ml M1 (blocking mAb anti-II.,1KI) or M22 (blocking mAb anti-IL-1RII) (16, 17) kindly provided by Dr. J. E. Sims, and incubated at 4~ for 4 h. After addition of I mM disuccinimidyl suberate from Pierce Chemical Co. (Rockford, IL) at 4~ for 30 min, samples were analyzed by 8% SDS-PAGE under reducing conditions, and dried gels were exposed to autoradiography for 1-3 d.
11_,6 and 11_,8
Production. PMN were exposed for 30 min to FMLP or medium. After washing, the cells were pulsed with 20 ng/ml of IL-1/3 for 4 h. Finally, cells were washed and incubated for an additional 24 h. The supernatants were collected and tested for IL-8 production by ELISA assays (the antibodies were from Dr. M. Ceska, Sandoz Forschung Institut, Vienna, Austria) and for IL-6 production by bioassay, using the 7TD1 hybridoma cell line as previously described (18) .
StatisticalAnalysis. The differences among experimental groups
were tested by the Student's t test. Table 1 summarizes the effects of various agents representative of different classes of chemoattractants (formylated peptides, complement components, lipids, chemokines) on the capacity of PMN to bind 125I-IL-1B. The different concentrations of the stimuli were chosen according to their optimal activity in the chemotactic assay. Results in Table 1 are a compound of different experiments and are presented as the percentage of binding relative to control at the 30-min time point. FMLP, C5a, LTB4, PAF, and IL-8 caused reductions of IL-1 binding to PMN of 80% (ranging from 73 to 94%), 50% (from 43 to 54%), 52% (from 47 to 66%), 37% (from 11 to 30%), and 25% (from 21 to 37%), respectively. The formyl peptide N-t-Boc-Met-Leu-Phe, an inactive FMLP receptor antagonist, caused no reduction at high concentrations (10-4 M) and partially inhibited the activity of FMLP. MCP-1, a chemokine that is inactive on PMN as a chemoattractant, caused no loss of IL-1 binding capacity. The signal transduction pathways of chemotactic factor serpentine receptors in- clude activation of PKC and a rapid increase in intracellular free Ca + +. The protein kinase C (PKC) activator PMA and the Ca ++ ionophore A23187 mimicked chemoattractants by causing rapid loss of IL-1 binding capacity. Subsequent analysis was conducted, mostly with the prototypic chemoattractant FMLP.
Results

Effects of PMN Chemoattractants on IL-I Binding.
Decreased IL-I Binding Is Determined by Loss of Surface IL-1R.
Having found that FMLP drastically reduced IL-1 binding to PMN, we examined whether this effect was due to a change in receptor affinity and/or a reduction in receptor number. (Fig. 2) . However, reduction of IL-1/3 binding induced by FMLP in PMN was rapid and pronounced. As shown in Fig. 2 , IL-1/3 binding was reduced by 50% at 30 s, the earliest measurable time point. Maximal reduction was reached after 30 rain. Thereafter, no further consistent reduction of IL-1 binding on treated PMN was evident (not shown). A dose-response curve of FMLP is shown in Fig. 3 , in which PMN from the same preparation were tested in parallel for IL-13 binding and chemotaxis. The half-maximal response was reached for both IL-13 binding loss and chemotaxis at ~5 x 10 -9 M. The two activities considered, IL-1 binding loss and chemotaxis, peaked at the same FMLP concentration (10 -7 M). At higher doses (10-s-10 -6 M), reduction of IL-1 binding was similar to the optimal concentration, whereas the chemotactic response at 10-5 M was ~70% of the maximal response. On the basis of these results, PMN were routinely incubated with 10-7 M FMLP for 30 rain at 37~ Release of the IL-1 Decoy RII. IL-1 binding sites could disappear from cell surface by internalization or release. As shown in Table 2 , the internalization process of receptor-bound IL-1 was not affected by FMLP, in that the percentage of internalized IL-1R was not different at all the time points studied, in untreated versus FMLP-treated cells. To examine the possibility that FMLP induced the release of IL-1R from treated PMN, cells were incubated with FMLP, and the cellfree supernatants were recovered and examined by cross-linking with 125I-IL-1B. As shown in Fig. 4 , FMLP-treated PMN released an IL-l-binding molecule of ~45 kD (after subtraction of the IL-1B molecular weight). The specific nature of the cross-linking was demonstrated by competition with an excess of unlabeled IL-1. IL-1 binding product was totally inhibited by the presence of a blocking mAb (M22) directed against the IL-1 decoy RII but not by an anti-IL-1RI mAb (M1). These observations were confirmed and extended to other stimuli that induced reduction of IL-1 binding on human PMN. As shown in Fig. 4 , C5a and A23187 also induced the release by PMN of an IL-l-binding molecule identified 
Specificity of lL-1 Binding Loss Induced by FMLP, To study
the specificity of FMLP-induced reduction of IL-1 binding, PMN treated with FMLP 10-7 M were examined for the expression of other surface molecules. As shown in Table 3 
Role of Protein Synthesis and Proteolytic Enzymes. IL-1
binding loss on PMN treated with FMLP did not require de novo protein synthesis. As shown in Table 4 , the presence of the protein synthesis inhibitor CH did not affect the reduc- To test whether proteolytic cleavage could be responsible for FMLP-induced release of IL-1 decoy KII, PMN were treated with FMLP in the presence or absence of different protease inhibitors (Table 5) . All the inhibitors were tested at the highest nontoxic dose (trypan blue dye exclusion) as assessed in preliminary experiments (data not shown). PMSF at 1 mM only partially blocked the effect of FMLP (44-56% inhibition of FMLP activity). T I C K inhibited FMLP effect by 36% at 0. Cells were incubated with FMLP (10 -7 M) survival (4), with 59 _+ 12% surviving cells at 48 h compared to 49 + 3% of cells exposed to IL-1 alone (mean _+ SD of three experiments).
Discussion
The results presented here show that molecules representative of different classes of chemotactic agents, including formyl peptides, complement components, lipid metabolites, and chemokines, cause rapid loss of IL-1R from human PMN. Receptors for the chemoattractants considered in the present study are seven transmembrane-spanning proteins coupled to G proteins. By and large, increases in intracellular flee Ca + + and PKC activation are early events associated with chemoattractant activation of PMN (19) . The PKC activator PMA and the Ca + § ionophore A23187 mimicked the action of chemoattractants in causing rapid and extensive loss of IL-1 binding in PMN.
Loss of IL-1 binding capacity in chemoattractant-treated PMN was due to the disappearance of the receptors on the cell surface, and it was associated with the release of a 45-kD IL-l-binding molecule. The rate of IL-1R internalization was not affected by FMLP. The 45-kD IL-l-binding molecule was identified as the IL-1 decoy KII, which represents the main IL-1R in myelomonocytic cells and an anti-IL-1 pathway (2, 4, 11) .
Induction of IL-1 decoy RII release by chemoattractants was considerably selective, in that integral type I membrane (MHC class I, CD18, IL-SR) and phosphatidyl inositol-linked proteins (CD16) were unaffected under these conditions. Under very similar experimental conditions, various PMN activators, including chemoattractants, have been reported to cause rapid release of TNFR, and, under certain conditions, TNFR shedding is preferential for the p75 form (12, 20) . In the present study, we could not identify induction of release of the signal-transducing IL-1RI, in that, by size and mAb blocking, only the IL-1 decoy RII was present in the supernatants of chemoattractant-treated PMN. Since the IL-1RI is present in minute amounts on the surface of PMN (1, 2, 4), some release cannot be completely excluded at present. However, it should be noted that FMLP-treated PMN retain responsiveness to IL-1 in terms of weak cytokine production and prolongation of survival. It was previously demonstrated that the response of myelomonocytic cells to IL-1 is mediated by the signal-transducing IL-1RI (3, 4) . Thus, the maintenance of IL-1 responsiveness in FMLP-treated myelomonocytic cells suggests, at minimum, that su~cient numbers of the IL-1RI are retained in the face of loss of 70-80% IL-1 decoy RII. By and large, these data, showing IL-1 responsiveness after shedding of 70-80% IL-1 decoy RII, are consistent with the viewpoint that this molecule is not involved in signal transduction in myelomonocytic cells.
We previously found that certain cytokines (IL-4, IL-13) and glucocorticoid hormones augmented IL-1 decoy RII in PMN, in a transcription-and protein synthesis-dependent way (4, 10, 11) . Up-regulation of newly synthesized receptor on PMN surface was paralleled by the release of soluble IL-1 decoy RII from PMN cultivated for a relatively long period of time (>12 h) (4, 10, 11) . Others found a soluble IL-1 decoy RII in biological fluids or supernatants from mitogen-activated mononuclear cells (5-9). Here we describe a different mechanism of release of the IL-1 decoy RII, in which shedding of preformed IL-1 decoy RII from the PMN surface is obtained in seconds and does not require protein synthesis. It is interesting to note that the above-mentioned stimuli were poorly effective in inducing the rapid release of IL-1 decoy RII (our unpublished data), suggesting that at least two different levels of control, activated by different classes of external signals, exist.
The biochemical process involved in rapid release of IL-1 decoy KII from activated PMN is still poorly understood. In the limited series of protease inhibitors tested here, certain molecules could, at least partially, prevent FMLP-induced release of IL-1 decoy RII. Interestingly, the protease inhibitor oll-antitrypsin was the most effective one. Since we found that intact protein synthesis is not required for FMLP-induced release of IL-1 decoy RII, these data favor the possibility that a preformed proteolytic enzyme is involved. Rapid release of TNFR was not inhibited by PMSF or by other protease inhibitors (12) , possibly suggesting that mechanisms involved in rapid release of IL-1R and TNFR from FMLP-activated PMN could be different.
In addition to migration, chemoattractants cause a complex spectrum of responses in PMN, including the oxidative burst and enzyme release. Typically, myelomonocytic cells exhibit different dose-response curves in terms of migration versus other functions. Chemotaxis dose-response curves are usually bell shaped, with EDs0 considerably lower (usually 1 log) than those required, for instance, for oxidative burst. In the present study, we found that, with FMLP, the EDs0 and peak concentrations for chemotaxis and for IL-1 decoy RII release were identical, though IL-1 decoy RII shedding did not decrease substantially at supraoptimal agonist concentrations. In the same vein, FMLP-induced release of IL-1 decoy RII was extremely rapid, reaching 50% of maximum at 30 s, the earliest measurable time point. The effective concentration range, similar to that required for chemotaxis, and the time frame (seconds) of chemoattractant-induced IL-1 decoy KII release are consistent with the view that, in the multistep process of PMN recruitment, IL-1 decoy RII shedding is an early event, already occurring in the blood compartment.
The in vivo pathophysiological significance of chemoattractant-induced IL-1 decoy RII and TNFK (12) release is a matter of speculation. Administration of chemoattractants in the circulation causes inhibition of local inflammatory reactions elicited by various agents, including IL-1 (21) (22) (23) . Rapid release of IL-1 decoy RII and TNFR might contribute to the seemingly paradoxical antiinflammatory activity of systemically administered chemoattractants. Chemoattractant-induced release in the circulation of IL-1 decoy RII, an early event in recruitment, may provide a safeguard mechanism against IL-1 leaking from inflamed tissues.
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